Why the study?
Can a pharmacokinetic-pharmacodynamic model describe the development of hypertension and proteinuria in cancer patients treated with E7080?
Can a pharmacokinetic-pharmacodynamic model describe the development of hypertension and proteinuria in cancer patients treated with E7080?
A PK-PD model successfully described the development of hypertension and proteinuria in cancer patients treated with E7080, which may help guide clinical interventions and dose adjustments.
No takes yet. Share an insight, caveat, or question.
May aid toxicity monitoring with E7080; extends PK-PD modeling to multitargeted TKIs but leaves open prospective validation.
Keizer et al. (2010) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: